Follow the patient from the first test to treatment and beyond
NeoGenomics Patient Journey connects longitudinal clinicogenomic data across the full patient timeline. From initial diagnosis to biomarker testing, through therapy selection, response, and disease progression, understand what actually happens to patients after a result, not just what the result was.
Quantify how long it takes from a positive biomarker result to therapy initiation by HCP, account, and territory, and identify where that gap is widest.
Linked clinicogenomic data supports time-to-event analyses, treatment sequencing studies, and resistance-mechanism exploration, the kind of RWE Medical Affairs teams need for high-impact publications.
Understand the full clinical and economic burden of a tumor type across the patient journey, from initial workup costs through treatment lines, supported by linked claims data.
Match your trial's inclusion/exclusion criteria against real patient profiles to identify eligible patients and high-volume investigator sites before you recruit.
Most patient journey datasets are built from claims codes. NeoGenomics Patient Journey starts with the actual lab result.
| Lab-confirmed biomarker status Every biomarker data point comes from an actual test result — not a diagnosis code used as a proxy. | vs. claims: inferred from billing codes |
| Exact test timing We know the precise date a test was ordered, resulted, and linked to a treating provider — not approximated from claim dates. | vs. claims: date-of-service lag |
| Community-representative population 85%+ of our testing comes from community oncology (not academic centers) reflecting where patients are actually treated. | vs. registry data: academic-center bias |
